AstraZeneca, Merck Say Lynparza Improved Overall Survival of Early Breast Cancer Patients
16 März 2022 - 7:31PM
Dow Jones News
By Will Feuer
AstraZeneca PLC and Merck & Co. said its Lynparza drug was
demonstrated in its Phase 3 trial to improve the overall survival
of certain patients with high-risk early breast cancer who have
been treated with neoadjuvant or adjuvant chemotherapy.
In the trial, called OlympiA, Lynparza reduced the risk of death
by 32%, compared with when patients only received the placebo
treatment, the companies said.
AstraZeneca said earlier this week that the drug was approved in
the U.S. as an additional treatment for patients with early breast
cancer who have already been treated with chemotherapy either
before or after surgery after the drug reached its primary endpoint
by significantly improving invasive disease-free survival.
Improving overall survival was a key secondary endpoint of the
trial, the companies said.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
March 16, 2022 14:16 ET (18:16 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
